Vaginal administration of estradiol: Effects of dose, preparation and timing on plasma estradiol levels

Climacteric

Volumn 18, Issue 2, 2015, Pages 121-134

  Santen, R J ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

absorption; estrogen; menopausal; side effects; systemic; Vaginal

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABSORPTION; ARTICLE; CHRONIC DRUG ADMINISTRATION; DATA ANALYSIS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRUG SYNTHESIS; HORMONE DETERMINATION; HUMAN; LOW DRUG DOSE; MEDLINE; OSTEOLYSIS; PREMENOPAUSE; PRIORITY JOURNAL; PUBLICATION; SENSITIVITY AND SPECIFICITY; TABLET; VAGINA ATROPHY; VAGINA MUCOSA; VAGINA RING; ATROPHY; BLOOD; DOSE RESPONSE; DRUG EFFECTS; FEMALE; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; TIME; VAGINA;

ADMINISTRATION, INTRAVAGINAL; ATROPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDLINE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VAGINA;

EID: 84924706283     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.947254     Document Type: Article

References (58)

1. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US offi ce-based physicians, 2000-2009. Menopause 2011; 18: 385-92
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
3. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Systematic Rev 2006; (4): CD001500
4. Mandel F P, G eola F L, M eldrum D R, e t a l. B iological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983; 57: 133-9
5. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978; 298: 195-7
6. Holmgren PA, Lindskog M, von SB. Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy. Maturitas 1989; 11: 55-63
7. Nilsson K, H eimer G. L ow-dose 17 beta-oestradiol during maintenance therapy-a pharmacokinetic and pharmacodynamic study. Maturitas 1995; 21: 33-8
8. Eugster-Hausmann M, Waitzinger J, Lehnick D. Minimized estradiol absorption with ultra-low-dose 10 g 17 estradiol vaginal tablets. Climacteric 2010; 13: 219-27
9. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002; 99: 556-62
10. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Effi cacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008; 111: 67-76
11. Handa V L, B achus K E, J ohnston W W, R obboy S J, H ammond C B. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994; 84: 215-18
12. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007; 16: 1713-19
13. Pschera H, Hjerpe A, Carlstrom K. Infl uence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Invest 1989; 27: 204-7
14. Laboratory normal ranges. In Jameson JL, De Groot LJ, eds. Endocriology: Adult and Pediatric, 6th edn. Philadelphia: Saunders, 2010: 2812
15. Schiff I, T ulchinsky D, R yan K J. V aginal absorption of estrone and 17beta-estradiol. Fertil Steril 1977; 28: 1063-6
16. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7: 156-61
17. Vartiainen J, W ahlstrom T, N ilsson C G. E ffects and acceptability of a new 17 beta-oestradiol-releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 1993; 17: 129-37
18. Stumpf P G, Maruca J, Santen R J, Demers L M. Development of a vaginal ring for achieving physiologic levels of 17 beta-estradiol in hypoestrogenic women. J Clin Endocrinol Metab 1982; 54: 208-10
19. Simunic V, B anovic I, C iglar S, J eren L, P avicic B D, S prem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003; 82: 187-97
20. Long C Y, L iu C M, H su S C, W u C H, W ang C L, T sai E M. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006; 13: 737-43
21. Naessen T, R odriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17betaestradiol in elderly women. Am J Obstet Gynecol 2002; 186: 944-7
22. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen defi ciency-a pharmacokinetic and pharmacodynamic study. Maturitas 1992; 15: 121-7
23. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 2001; 27: 255-60
24. Mettler L, Olsen P G. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991; 14: 23-31
25. Martin PL, Greaney MO, Burnier AM, Brooks PM, Yen SS, Quigley ME. Estradiol, estrone, and gonadotropin levels after use of vaginal estradiol. Obstet Gynecol 1984; 63: 441-4
26. van Haaften M, D onker G H, H aspels A A, T hijssen J H. Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. J Steroid Biochem 1989; 33: 647-53
27. Smith P, H eimer G, L indskog M, U lmsten U. O estradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993; 16: 145-54
28. Ulrich L S, N aessen T, E lia D, G oldstein J A, E ugster-Hausmann M; VAG-1748 trial investigators. Endometrial safety of ultralow-dose Vagifem 10 g in postmenopausal women with vaginal atrophy. Climacteric 2010; 13: 228-37
29. Naessen T, B erglund L, U lmsten U. B one loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. Am J Obstet Gynecol 1997; 177: 115-19
30. Naessen T, R odriguez-Macias K, L ithell H. S erum lipid profi le improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001; 86: 2757-62
31. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005; 8: 83-92
32. Dorr MB, Nelson AL, Mayer PR, et al. Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil Steril 2010; 94: 2365-8
33. Santen RJ, Pinkerton JV, Conaway M, e t al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002; 9: 179-87
34. Dugal R, H esla K, S ordal T, A ase K H, L illeeidet O, W ickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000; 79: 293-7
35. Labrie F, C usan L, G omez J L, e t a l. E ffect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009; 16: 30-6
36. Felding C, Mikkelsen A L, Clausen H V, Loft A, Larsen L G. Preoperative treatment with oestradiol in women scheduled for vaginal operation for genital prolapse. A randomised, doubleblind trial. Maturitas 1992; 15: 241-9
37. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17: 584-7 Luisi
38. M, F ranchi F, K icovic P M. A group-comparative study of effects of Ovestin cream versus Premarin cream in post-menopausal women with vaginal atrophy. Maturitas 1980; 2: 311-19
39. http://rxlist.com/femring-drug/clinical-pharmacology.htm
40. Utian W H, S houpe D, B achmann G, P inkerton J V, P ickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065-79
41. Crandall C. Low-dose estrogen therapy for menopausal women: a review of effi cacy and safety. J Women's Health 2003; 12: 723-47
42. K rause M, W heeler T L, R ichter H E, S nyder T E. S ystemic effects of vaginally administered estrogen therapy: a review. Female Pelvic Med Reconstr Surg 2010; 16: 188-95
43. Al-Azzawi F, Lees B, T hompson J, S tevenson J C. B one mineral density in postmenopausal women treated with a vaginal ring delivering systemic doses of estradiol acetate. Menopause 2005; 12: 331-9
44. Al-Azzawi F, Buckler HM, United Kingdom Vaginal Ring Investigator Group. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric 2003; 6: 118-27
45. Crandall C. Vaginal estrogen preparations: a review of safety and effi cacy for vaginal atrophy. J Women's Health 2002; 11: 857-77
46. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 903;20: 888-902
47. Santen RJ, Allred DC, Ardoin SP, e t al. Postmenopausal hormone therapy: an Endocrine Society scientifi c statement. J Clin Endocrinol Metab 2010; 95(Suppl 1): Sl-66
48. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of theWomen's Health Initiative randomized trials. JAMA 2013; 310: 1353-68
49. Key T, Appleby P, B arnes I, Reeves G, E ndogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-16
50. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer 2005; 12: 1071-82
51. Key TJ, Appleby PN, Reeves GK, et al.; Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011; 105: 709-22
52. Henriksson L, S tjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of effi cacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996; 174: 85-92
53. Del P L, D i F R, C avaliere C, et a l. P romestriene, a specifi c topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients Anti-Cancer Drugs 2013; 24: 989-98
54. Stute P. I s vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief Arch Gynecol Obstet 2013; 288: 1199-201
55. Santen RJ, Lee JS, W ang S, et al. P otential role of ultra-sensitive estradiol assays in estimating the risk of breast cancer and fractures. Steroids 2008; 73: 1318-21
56. Santen RJ, Demers L, Ohorodnik S, et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007; 72: 666-71
57. Torres-Santiago L, Mericq V, Taboada M, et al. Metabolic effects of oral versus transdermal 17beta-estradiol (E2): a randomized clinical trial in girls with Turner syndrome. J Clin Endocrinol Metab 2013; 98: 2716-24
58. Klein KO, D emers LM, S antner SJ, B aron J, C utler GB, J r., S anten RJ. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 1995; 80: 2658-60